Biora Therapeutics Announces New Patent Covering Its BioJet Liquid Jet Delivery Technology
Portfolio Pulse from Benzinga Newsdesk
Biora Therapeutics, Inc. (NASDAQ:BIOR) announced the issuance of a new patent by the USPTO for its BioJet platform, which enables oral, systemic delivery of biotherapeutics through liquid jet delivery to the small intestine. The patent covers key parameters for this technology, which has shown promising preclinical results, including systemic bioavailability comparable to subcutaneous injections. Biora's BioJet platform could revolutionize the oral delivery of large molecule drugs, with the company holding a strong patent position in this area.
April 08, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biora Therapeutics has been granted a new patent for its BioJet liquid jet delivery technology, which could significantly enhance the oral delivery of biotherapeutics.
The issuance of a new patent strengthens Biora Therapeutics' intellectual property portfolio, specifically in the innovative field of oral drug delivery. This technological advancement, showing comparable bioavailability to traditional injections, positions BIOR for potential growth and partnerships in the biotech industry. The comprehensive patent coverage, including 12 issued patents and 31 pending applications for the BioJet platform, further solidifies BIOR's competitive edge and could attract investor interest due to the platform's potential to transform oral delivery of therapeutics.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100